Feb 5, 2024, 11:27
Stephen V Liu: The optimal strategy for unresectable stage III NSCLC after chemoradiation in EGFR mutant NSCLC
Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Lombardi Comprehensive Cancer Center, posted on X/Twitter:
“What is the optimal strategy for unresectable stage III NSCLC after chemoradiation in EGFR mutant NSCLC? Retrospective look JTO and JTO CRR (n=136) shows 2y rwPFS rate 86% with osimertinib, 30% with durvalumab, 27% with observation. Await prospective data from the phase III LAURA trial.
Point against immunotherapy: In 45 patients who progressed after consolidation durvalumab (PACIFIC), 37 then received EGFR TKI therapy. In those patients, 38% develped trAEs including 14% pneumonitis and 14% diarrhea.”
Read further.
Source: Stephen V Liu/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 09:31
Nov 14, 2024, 09:26
Nov 14, 2024, 09:21
Nov 14, 2024, 09:15
Nov 14, 2024, 00:19